evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 9 findings · 5 reviews · Stroke

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 3 · 33.3%Moderate 2 · 22.2%High 3 · 33.3%

Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (low certainty).

1 finding from 1 review

Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

Thrombo‐aspiration alone vs stent‐retrieval thrombectomy alone

All‐cause mortality within 3 months · people with acute ischemic stroke

Thrombo‐aspiration alone showed no clear difference in all‐cause mortality within 3 months compared with stent‐retrieval thrombectomy alone (high certainty).

1 finding from 1 review

TDC vs medical therapy

Death from any cause (secondary outcome 3) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

TDC showed no clear difference in secondary outcome: all‐cause mortality at the end of compared with medical therapy (low certainty).

1 finding from 1 review